pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vidaza
drug · small molecule
save

azacitidine

Phase 2updated 6mo ago
by Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 8
  • drugOnureg21 co-mentions · 9 sources
  • tagApproval12 co-mentions · 3 sources
  • tagSmall Molecule8 co-mentions · 4 sources
  • tagAML7 co-mentions · 2 sources
  • tagOncology3 co-mentions · 2 sources
  • tagDrug Shortage3 co-mentions · 3 sources
  • tagPulmonology2 co-mentions · 1 sources
  • drugivosidenib2 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 49 investigational indications.

targets

DNA (cytosine-5)-methyltransferase 1DNA (cytosine-5)-methyltransferase 3A

all catalysts(0)

nothing on the calendar yet

Trials studying azacitidine

  • phase3A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patientsrecruitingn=318
  • phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLrecruitingn=1,300
  • phase2Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemiarecruitingn=49
  • phase2Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclaxrecruitingn=25
  • phase2A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemianot yet recruitingn=30
  • phase2Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemiaactive not recruitingn=11
  • phase2A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutationsrecruitingn=30
  • phase3Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).recruitingn=490

News(2)

  • BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
    Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.
    fiercebiotech · 2mo ago
  • Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
    Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.
    onclive · 6mo ago
brand
Vidaza
trade names
Azacitidine, Azacitidine accord, Azacitidine betapharm, Azacitidine celgene, Azacitidine kabi, Azacitidine mylan
generic
azacitidine
MOA
DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA (cytosine-5)-methyltransferase 3A inhibitor
indication
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?